X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
ABSK021 (pimicotinib) is a novel, orally available, highly selective, and potent small molecule CSF-1R inhibitor. It is being evaluated in phase 3 studies for the treatment of inoperable tenosynovial giant cell tumor (TGCT).
Lead Product(s): Pimicotinib
Therapeutic Area: Oncology Product Name: ABSK021
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 08, 2024
Details:
ABSK021 (pimicotinib) is a novel, orally available, highly selective, and potent small molecule CSF-1R inhibitor. It is being evaluated for for the treatment of tenosynovial giant cell tumor (TGCT).
Lead Product(s): Pimicotinib
Therapeutic Area: Oncology Product Name: ABSK021
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 13, 2023
Details:
Under the agreement, Merck will receive an exclusive license to commercialize ABSK021 (pimicotinib), an oral, highly selective and potent small-molecule antagonist of colony stimulating factor-1 receptor, currently in Phase III for tenosynovial giant cell tumor.
Lead Product(s): Pimicotinib
Therapeutic Area: Oncology Product Name: ABSK021
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Merck Group
Deal Size: Undisclosed Upfront Cash: $70.0 million
Deal Type: Licensing Agreement December 04, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
